| Literature DB >> 35924042 |
Chen-Chen Fu1,2, Fa-Ying Xu3, Yu-Chen Qian1,2, Hoi-Lun Koo4, Yi-Fan Duan1,2, Geng-Min Weng3, Tai-Ping Fan5, Mo-Xian Chen1,2, Fu-Yuan Zhu1,2.
Abstract
Osmanthus fragrans (scientific name: Osmanthus fragrans (Thunb.) Lour.) is a species of the Osmanthus genus in the family Oleaceae, and it has a long history of cultivation in China. O. fragrans is edible and is well known for conferring a natural fragrance to desserts. This flowering plant has long been cultivated for ornamental purposes. Most contemporary literature related to O. fragrans focuses on its edible value and new species discovery, but the functional use of O. fragrans is often neglected. O, fragrans has many properties that are beneficial to human health, and its roots, stems, leaves, flowers and fruits have medicinal value. These characteristics are recorded in the classics of traditional Chinese medicine. Studies on the metabolites and medicinal value of O. fragrans published in recent years were used in this study to evaluate the medicinal value of O. fragrans. Using keywords such as metabolites and Osmanthus fragrans, a systematic and nonexhaustive search of articles, papers and books related to the medicinal use of Osmanthus fragrans metabolites was conducted. Fifteen metabolites were identified through this literature search and classified into three categories according to their properties and structure: flavonoids, terpenes and phenolic acids. It was found that the pharmacological activities of these secondary metabolites mainly include antioxidant, anticancer, anti-inflammatory and antibacterial activities and that these metabolites can be used to treat many human diseases, such as cancer, skin diseases, cardiovascular diseases, and neurological diseases. Most of the reports that are currently available and concern the secondary metabolites of Osmanthus fragrans have limitations. Some reports introduce only the general classification of compounds in Osmanthus fragrans, and some reports introduce only a single compound. In contrast, the introduction section of this paper includes both the category and the functional value of each compound. While reviewing the data for this study, the authors found that the specific action sites of these compounds and their mechanisms of action in plants are relatively weak, and in the future, additional research should be conducted to investigate this topic further.Entities:
Keywords: Osmanthus fragrans; flavonoids; medicinal compound; phenolic acids; secondary metabolites; terpenoids
Year: 2022 PMID: 35924042 PMCID: PMC9340074 DOI: 10.3389/fphar.2022.922204
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.988
FIGURE 1Summary of the literature according to keywork and the year published over the last 10 years. (A) Bubble chart showing the number of publications in 5 years from the past 10 years. The horizontal axis is the publication year, and the vertical axis is the relevant keyword used to search the literature. Correlative studies are relatively weak, and studies of various secondary metabolites are clearly differentiated. (B) Heatmap showing the prevalence of keywords in publications over the past 10 years. The figure shows that the research statuses of the three major categories of secondary metabolites selected in this paper are very different, with research on flavonoids being the most extensive and research on phenolic acids being the least extensive. (The basic principle of the author’s preliminary background investigation before writing this manuscript is to first conduct a general search on the research progress of O. fragrans, select compounds extracted from O. fragrans, and then screen out relatively important secondary metabolites of O. fragrans).
Fifteen major secondary metabolites in O. fragrans.
| Small molecule | Structure | Chemical properties | Mechanism and pathways | Related experimental information | References |
|---|---|---|---|---|---|
| Flavonoids | |||||
| Diosmetin |
| Yellow powder | Exerts anti-inflammatory, antibacterial, and antioxidant effects; affect the activation of thePI3K/Akt and NF-κB signalling pathways | The cardiomyocyte cell line H9c2 derived from the rat; Dosages: 5, 10, or 15 μg/ml; cells were incubated in normoxia for 1 h, then in hypoxia for 48 h | ( |
| Dihydroquercetin |
| Pale yellow or colorless needle-like crystals | Protect the kidneys. Affect the mTORC2/Akt signalling pathway | 65 adult male SD rats weighing 220–240 g; treatment doses of 50 mg/kg, 100 mg/kg, 200 mg/kg for 12 weeks; Urine is collected and blood drawn after experimental treatment |
|
| Astilbin |
| White crystalline powder | Protect the nervous system.Affect the PI3K/Akt and MAPK pathways | 20 adult male rats; 50 mg kg −1 pretreated for 2 h. Analysis after 24 h of reperfusion C57BL/6 mice |
|
| Luteolin |
| Yellow needle-like crystals | Anti-gout, exerts antitumour effects; enhances memory. Inhibits the production of the inflammatory factors TNF-α and IL-1β | 50 ICR mice were treated for about 7 days, dosage: 20, 40, 80 mg/kg |
|
| Naringenin |
| Yellow powder | Protects against lung damage and ageing; Neuroprotection. Regulate the PKC, Akt, MAPK and other signalling pathways | Well differentiated PC12 cells; diluted gradients of 400, 40, 4, 0.4, 0.04, 4 × 10–3, 4 × 10–4, 4 × 10–5 μmol L−1 were used, 5 days | ( |
| Terpenoids | |||||
| Loganic acid |
| White crystalline powder | Exerts anti-lipogenesis and anti-osteoporosis effects. Reduce the expression of key adipogenesis-related genes such as adiponectin, lipoprotein lipase | 40 seven-week-old female OVX mice; doses: 2, 10 and 50 μg/ml. Oral for 12 weeks; Osteoblast MC3T3-E1 cells; dosage: 2, 10 and 50 μM | ( |
| Oleoside |
| Powder | Exerts antioxidative effects. Act as a free radical scavenging antioxidant and inhibits lipid peroxidation | Cell line HepG2; Dosage: 10–3, 10–4, 10–5, 10–6, 10–7 mol L−1; 36 h | ( |
| Secoxyloganin |
| Solid | Anti-virus, antitumor | Human breast cancer (MCF-7) and prostate cancer (PC-3) cell lines; Dosage: 10 μL; 24 h; 140 male guinea pigs weighing 300 ± 50 g | ( |
| Oleanolic acid |
| White needle-like crystals | Exerts anti-inflammatory effects, lowers blood lipid. Affects the JNK signalling pathway | Human cell line Eca109; Dosage: 10, 20, 40 μmol L−1 24 h | ( |
| Maslinic acid |
| Light yellow powder | Cellular oxidative damage protection. Influence the p38 and Nrf2/HO-1 pathways | Normal rat liver cell line (BRL-3A) Dosage: 5, 10, 15, 20, 25, 30 μmol/L; 8 h |
|
| Phenolic acids | |||||
| Tyrosol |
| Yellow-green fine powder | Prevents coronary heart disease, promote endothelial cell proliferation | Human microvascular endothelial cells (HMEC-1), Dosage: 7.5, 10, 15, 30, 40, 80 μM; 48 h |
|
| p-Hydroxyphenyl acetic acid |
| White crystalline powder | Neuroprotection. As a raw material for the synthesis of various drugs | Weigh 10 g (65.72 mmol) of p-Hydroxyphenyl acetic acid, dissolve it with methanol (100 ml) |
|
| Rosmarinic acid |
| Light yellow powder, white powder | Antiproliferative effect on human melanoma A375 cells. Interference with MAPK/ERK pathway leads to apoptosis | Human melanoma A375 cells, dosage: 1:120, 1:240, 1:480 and 1:960 dilutions; 72 h |
|
| Salicylic acid |
| White needle-like crystal or hairy crystalline powder | Treatment of plantar warts, treat skin diseases | 240 patients 12 years and older; dosage: 50%; 6 months; 90 patients with melasma; dosage: 20%; 12 weeks | ( |
| Protocatechualdehyde |
| Light beige needle crystals or off-white powder | Neuroprotective effect, promote bone healing. Down-regulation of GFAP and AQP-4 proteins in brain tissue | 48 male rats of 240–270 g; dosage: 10, 20 mg/kg; once a day for 5 consecutive days | ( |
The table introduces the structures and chemical properties of fifteen major secondary metabolites and briefly summarizes their medicinal properties and mechanisms. These properties include the ability to exert antioxidative, anti-ageing, neuroprotective, and antidepressant effects; lower blood lipid and blood sugar levels; and other properties. Relevant experimental information is provided.
FIGURE 2Representative medicinal compounds in O. fragrans and their biosynthetic pathways. (A) The main synthesis pathway containing naringenin, luteolin and DHQ in the flavonoid biosynthesis pathway is presented. Naringenin can produce luteolin and DHQ through reactions catalysed by different enzymes. (B) Loganic acid is a terpenoid. The synthetic pathway of loganic acid in the monoterpene biosynthesis pathway. Loganic acid can be produced from geraniol through reactions catalysed by a series of enzymes. (C) SA, PCA and Ty are synthesized via three different phenolic acid biosynthesis pathways, but the synthetic pathway of SA can be connected to the synthetic pathways of PCA and Ty. The double dotted arrow in the figure represents the connection between the pathways. (The relevant O. fragrans gene information in this biosynthetic pathway map comes from an article about O. fragrans published by) (Yang, et al., 2018).
FIGURE 3Representative medicinal compounds in O. fragrans and their pharmacological mechanisms of action. (A) Pathways by which Dio affects MH7A cell apoptosis. Dio inhibits the production of inflammatory mediators and cytokines (TNF-α, IL-1β, IL-6, etc.) induced by D-GalN and can also regulate the Akt/NF-kB pathway. Dio can also inhibit the PI3K/Akt pathway. PI3k is phosphorylated to generate Akt, and Akt is a key molecule in the activation of the NF-κB signalling pathway. Inhibition of this pathway reduces cell proliferation and inflammatory cytokine production in MH7A cells and promotes apoptosis. (B) Effects of DHQ on the mTORC2/Akt signalling pathway under high-glucose conditions. Reactive oxygen species (ROS) can activate the protein kinase PI3K signalling pathway. There are two downstream pathways of PI3k. In the one presented here, the PI3k-Akt signalling pathway affects mTORC2 and mTORC1. PI3k generates PIP3, PIP3 further activates PDK1, PDK1 activates Akt through phosphorylation, and Akt further activates mTORC2. DHQ has an inhibitory effect on ROS production. After the addition of DHQ, the activity of ROS is reduced, the regulatory effect of ROS on the PI3k pathway is weakened, the expression of Akt, which is downstream of PI3k, is decreased, and the expression of mTORC2, which is downstream of Akt, is inhibited. Akt phosphorylation can regulate GSK3 and reduce cell survival to ameliorate diabetic nephropathy in rats. (Red indicates increase/promotion, green indicates decrease/inhibition, and yellow indicates promotion of the original pathway but inhibition of this pathway.)
Medicinal efficacy of major secondary metabolites in Osmanthus fragrans.
| Metabolites | Location | Function |
|---|---|---|
| Geraniol | Flower | Anti-inflammatory, anti-cancer, anti-oxidant |
| Dihydroquercetin | Flower | Anti-virus, anti-apoptosis, anti-tumor |
| Astilbin | Flower | Anti-depressant, anti-diabetic, analgesic and antibacterial |
| Luteolin | Leaves | Anti-tumor, protect nervous system, enhance memory |
| Naringenin | Flower | Anti-inflammatory, anti-bacterial, anti-lung damage, anti-aging |
| Loganic acid | Flower | Anti-lipogenesis, anti-osteoporosis |
| Oleoside | Flower | Anti-oxidation |
| Serotonin | Flower | Antiviral, antitumor and antibacterial activity |
| Oleanolic acid | Flower, Seeds | Protect liver, lower enzymes, strengthen heart, lower blood fat |
| Maslinic acid | Flower | Anti-inflammatory, anti-fibrosis |
| Tyrosol | Flower | Prevent coronary heart disease and tumors, anti-oxidative stress |
| P-hydroxyphenylacetic acid | Flower | Analgesic and anti-inflammatory |
| Rosmarinic acid | Flower | Anti-microbial, anti-oxidant, inhibit kidney stones |
| Salicylic acid | Flower | Soften blood vessels and treat skin diseases |
| Protocatechualdehyde | Flower | Inhibit cell apoptosis, anti-septicemia |
| Ursolic acid | Seeds | Antitumor |
| Salidroside | Seeds | Lower blood sugar, anti-oxidation, anti-inflammatory |
| Linoleic acid | Seeds | Anti-oxidation |
| Melanin | Flower | Anti-oxidant, anti-aging |
| Palmitic acid | Flower | Anti-oxidation |
The table summarizes the structure and function of the 15 compounds in this paper and introduces the structure, function and medicinal value of secondary metabolites that do not appear but also come from Osmanthus fragrans.